

BROWN RAYSMAN

BROWN RAYSMAN MILLSTEIN FELDER & STEINER

RECEIVED
CENTRAL FAX CENTER

MAR 03 2004

FACSIMILE COVER SHEET**OFFICIAL**

From:	James Demers	Date:	March 3, 2004
Direct Dial:	212-895-2683	Client/Matter #:	6319/11US

PLEASE DELIVER AS SOON AS POSSIBLE TO:

	Recipient	Company	Fax No.	Phone No.
1.	Howard Owens Jr. Art Unit 1623	USPTO	703-872-9306	

Total number of pages including this page: **5**
If you do not receive all the pages, please call **212-895-2984**.

Message:

Docket No.	:	6319/11US
Application of	:	Robert TAM
Application No.	:	09/624855
Filing Date	:	June 25, 2000
Art Unit	:	1623
Examiner	:	Howard V. Owens Jr.
Title	:	Specific Modulation of TH1/TH2 Cytokine Expression by Ribavirin in Activated T-Lymphocytes

Please find enclosed:

- REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS
- STATEMENT UNDER 37 C.F.R. 3.73(b)
- COPY OF ASSIGNMENT OF PATENT

PTO/SB/82 (09-03)

Approved for use through 11/30/2005. OMB 0851-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REVOCATION OF POWER OF
ATTORNEY WITH
NEW POWER OF ATTORNEY
AND
CHANGE OF CORRESPONDENCE ADDRESS**

Application Number	09/624855
Filing Date	07/25/2000
First Named Inventor	Robert Tam
Art Unit	1823
Examiner Name	Howard V. Owens Jr.
Attorney Docket Number	6319-11

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint the practitioners associated with the Customer Number:

29858

☐ Please change the correspondence address for the above-identified application to:☒ The address associated with
Customer Number:

29858

OR

☐ Firm or
Individual Name

Address

Address

City

State

Zip

Country

Telephone

Fax

I am the:

☐ Applicant/Inventor.☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)**SIGNATURE of Applicant or Assignee of Record**

Name

Signature

Date

Telephone

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

02/27/2004 FRI 19:00 [TX/RX NO 7435] 002

PTO/SB/86 (08-03)

Approved for use through 07/31/2008, OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Ribapharm Inc., 3300 Hyland Ave., Costa Mesa CA 92626

Application No./Patent No.: 09/824855 Filed/Issue Date: 07/25/2000

Entitled: Specific Modulation of Th1/Th2 Cytokine Expression by Ribavirin in Activated T-LymphocytesRibapharm Inc. a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %
in the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☐ Copies of assignments or other documents in the chain of title are attached.
(NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08)

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Feb 24, 2004
Date
714-427-6236 x3086
Telephone number

KIM D. LAMON
Typed or printed name
[Signature]
Signature
PRESIDENT + CSO
Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

02/27/2004 FRI 19:00 [TX/RX NO 7435] 003

09/624,855

Docket No. 6319-11

ASSIGNMENT OF PATENT

WHEREAS I, Robert Tam, residing at 63 Wellington St., Irvine CA 92618, have made an invention entitled

**SPECIFIC MODULATION OF TH1/TH2 CYTOKINE EXPRESSION BY
RIBAVIRIN IN ACTIVATED T-LYMPHOCYTES**

and have filed for said invention the following application for a United States Patent,

Application No.: 09/624,855
Filing date: July 25, 2000;

and

WHEREAS, Ribapharm Inc., here referred to as ASSIGNEE, a corporation having an office and place of business at 3300 Hyland Avenue, Costa Mesa, CA 92626 is desirous of acquiring the entire interest in said invention, in said United States patent application, and in any Letters Patent which may issue thereon;

NOW, THEREFORE, be it known that for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, I do hereby sell, assign and transfer unto ASSIGNEE, its successors, and assigns, all right, title and interest in and to said invention and any improvements thereon for all countries of the world, and in and to said United States patent application, including any continuations and divisions thereof, and the right to claim priority based on said patent application, and any patent which may issue thereon and any reissues of the same; and all right, title and interest in and to every patent application filed or to be filed on said invention in any other country, including renewals, revivals, continuations and divisions thereof, and any and all patents which may issue thereon and any reissues and extensions of the same; and I hereby authorize and request competent authorities in all national Patent Offices to grant and issue any and all patents on said invention to ASSIGNEE; and I further agree to execute upon request of ASSIGNEE such additional documents as are necessary and proper to secure patent protection on said invention throughout all countries of the world and to otherwise give full effect to and perfect the rights of ASSIGNEE under this Assignment.

- 1 -

BRMFS1 469315v1

02/27/2004 FRI 19:00 [TX/RX NO 7435] 004

09/624,855


Docket No. 6319-11

Executed this 27th day of February, 2004 at Costa Mesa, Californiaby: *Robert Tam*
Robert TamSTATE OF CALIFORNIA)
ORANGE COUNTY)

ss:

On February 27, 2004, before me, Pamela Chronister Lewis, personally appeared Robert Tam, personally known to me to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.

Pamela Chronister Lewis
Notary Public

- 2 -

BRMFS1 469315v1

TOTAL P.05

02/27/2004 FRI 19:00 [TX/RX NO 7435] 005